Duality Biotherapeutics, Inc. (DualityBio) disclosed a marginal adjustment to its share capital following concurrent on-market repurchases and option exercises on 6 November 2026.
Share Repurchase • Volume: 8,500 ordinary shares were bought back on the Hong Kong Stock Exchange. • Consideration: HK$889,210 at a volume-weighted average price of HK$104.61 per share (high: HK$104.90; low: HK$104.00). • Capital Impact: The repurchased amount equals 0.009 % of the 91.05 million issued shares (ex-treasury) outstanding before the transaction. All repurchased shares have been retained as treasury stock, lifting the treasury-share balance to 896,200.
Option Exercise • Volume: 9,200 new ordinary shares were issued upon the exercise of options granted under the company’s Pre-IPO Equity Incentive Plan (adopted 28 Feb 2021; amended 25 Jun 2023). • Issue Price: HK$9.90 per share (volume-weighted average).
Post-Transaction Share Capital • Issued shares (ex-treasury): 91,046,797, up by a net 700 shares versus the previous day’s 91,046,097. • Treasury shares: 896,200. • Total shares in issue (including treasury): 91,942,997.
Repurchase Mandate Status • Authorised limit (approved 26 Jun 2026): 9.06 million shares. • Cumulative shares repurchased under the mandate: 569,900, representing 0.63 % of the issued share base when the mandate was granted. • A 30-day moratorium on new share issues or treasury-share sales is in effect until 6 December 2026, in line with Hong Kong listing rules.
Regulatory Compliance The company confirmed that the board duly authorised the transactions and that all applicable Hong Kong Stock Exchange listing rules and relevant legal requirements have been met.
Comments